// App-Quantinova.ai

2472 : Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis

Researchers

Presenter

  • Daniel Aletaha

Principal Investigators

  • Carter Thorne

  • Michael Schiff

  • Masayoshi Harigai

  • Prasheen Agarwal

  • Ravi Rao

  • Christopher Cohen

  • Ben Cheng

  • Kurt Brown

  • Benjamin Hsu

Medical Centers

  • Department of OB/GYN, Division of Senology, Medical University of Vienna, Vienna, Austria

  • University of Toronto, Newmarket, Canada

  • University of Colorado Denver School of Medicine, Aurora, CO

  • Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

  • Janssen Research and Development, LLC, Spring House, PA

  • GlaxoSmithKline, Hertfordshire, United Kingdom.

  • GlaxoSmithKline, Collegeville, PA

Locations

  • Austria

  • Canada

  • United States

  • Japan

  • United Kingdom

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Cytokine

  • Interleukin 6

Drug/Treatment

  • sirukumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved